
About Evoq Remedies Limited
Data last updated:
Evoq Remedies Limited is a public limited company based in Ahmedabad, Gujarat, India. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 February 2010.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L46209GJ2010PLC059692. Its GSTIN is 24AAZCS6618L1ZI (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 543500.
The company has an authorised share capital of ₹42 Cr and a paid-up capital of ₹24.9 Cr. It was formerly known as Evoq Remedies Private Limited and Salus Life Science and Research Private Limited. It is led by directors including Bhumishth Narendrabhai Patel (Managing Director) and Pushpa Joshi.
Its last annual general meeting (AGM) was held on 17 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Ahmedabad, Gujarat.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹25.51 Cr, a growth of 116.9% compared to the previous year. For the same year it recorded a net loss of ₹24 Lakh (net margin -0.9%) and EBITDA of -₹1.45 Cr (EBITDA margin -5.7%).
The company is associated with 1 brand: EVOQ Remedies. Court records list 1 case involving the company, including 1 filed by the company. The company has 51 deals on record (41 market trades, 6 secondary share transfers, 3 funding rounds), with disclosed funding of ₹60.57 Cr; the latest was in June 2026.
The last known website on record is evoqremedies.com.
Company details
Name history
Evoq Remedies has undergone 2 name changes throughout its history. The company was previously known as Evoq Remedies Private Limited, and Salus Life Science And Research Private Limited. The current legal name is Evoq Remedies Limited.
| Company Name | Status |
|---|---|
| Evoq Remedies Limited | Current |
| Evoq Remedies Private Limited | Previous |
| Salus Life Science And Research Private Limited | Previous |
CIN history
Evoq Remedies has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L46209GJ2010PLC059692, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L46209GJ2010PLC059692 | Current |
| U24230GJ2010PLC059692 | Previous |
| L24230GJ2010PLC059692 | Previous |
| U24230GJ2010PTC059692 | Previous |
Contact details
Evoq Remedies Limited's registered office is in Ahmedabad, Gujarat.
- Registered AddressA – 1106 Empire Business Hub Near Auda Water Tank Science City Road, Sola, Ahmedabad, Gujarat, India – 380060
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Evoq Remedies operates one associated brand: EVOQ Remedies. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| CDMO focused on manufacturing pharmaceutical formulation and marketing services | evoqremedies.com |
Financials of Evoq Remedies Limited
FY 2025-26 filings availableEvoq Remedies Limited reported revenue of ₹25.51 Cr (up 116.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 25.51 | 11.76 | 4.05 | 20.39 | 16.78 | 10.02 | 9.07 |
| Revenue growth | +116.9% | +190.4% | -80.1% | +21.5% | +67.5% | +10.5% | - |
| EBITDA | (1.45) | (2.24) | (1.65) | (3.73) | 1.45 | 0.95 | 0.00 |
| EBITDA margin | -5.7% | -19.1% | -40.7% | -18.3% | +8.6% | +9.5% | 0.0% |
| Profit before tax | (0.25) | 0.12 | 0.60 | 2.29 | 1.45 | 0.95 | 0.00 |
| Net profit | (0.24) | 0.08 | 0.44 | 1.62 | 1.08 | 0.71 | 0.00 |
| Net profit margin | -0.9% | +0.7% | +10.9% | +8.0% | +6.4% | +7.1% | 0.0% |
| EPS (₹) | (0.10) | 0.04 | 0.33 | 1.19 | 0.80 | 715.45 | 0.30 |
| Balance sheet | |||||||
| Total assets | - | 44.54 | 29.48 | 34.36 | 31.32 | 0.74 | 0.03 |
| Net worth | - | 44.54 | 25.24 | 24.79 | 23.17 | 0.74 | 0.02 |
| Total debt | - | 0.00 | 4.24 | 9.58 | 8.16 | 0.00 | 0.01 |
| Cash & bank | - | 0.21 | 0.12 | 0.15 | 3.09 | 0.03 | 0.00 |
| Net working capital | - | 44.31 | 29.47 | 34.35 | 31.32 | 0.74 | 0.03 |
| Cash flow | |||||||
| Cash from operations | - | (14.62) | 5.32 | (4.35) | (26.43) | 0.03 | (0.02) |
| Cash from investing | - | (0.26) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 |
| Cash from financing | - | 14.97 | (5.34) | 1.42 | 29.49 | 0.00 | 0.00 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 25.51 | 11.76 | 4.05 | 20.39 | 16.78 | 10.02 | 9.07 |
| Revenue growth | +116.9% | +190.4% | -80.1% | +21.5% | +67.5% | +10.5% | - |
| Other income | 1.25 | 2.41 | 2.26 | 6.02 | 0.00 | 0.00 | 0.00 |
| Total expenses | 26.96 | 14.00 | 5.70 | 24.12 | 15.33 | 9.07 | 9.07 |
| Employee cost | 0.00 | 0.07 | 0.08 | 0.20 | 0.18 | 0.01 | 0.01 |
| EBITDA | (1.45) | (2.24) | (1.65) | (3.73) | 1.45 | 0.95 | 0.00 |
| EBITDA margin | -5.7% | -19.1% | -40.7% | -18.3% | +8.6% | +9.5% | 0.0% |
| Depreciation | 0.05 | 0.05 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.25) | 0.12 | 0.60 | 2.29 | 1.45 | 0.95 | 0.00 |
| Tax | (0.01) | 0.04 | 0.16 | 0.67 | 0.37 | 0.24 | 0.00 |
| Net profit | (0.24) | 0.08 | 0.44 | 1.62 | 1.08 | 0.71 | 0.00 |
| Net profit margin | -0.9% | +0.7% | +10.9% | +8.0% | +6.4% | +7.1% | 0.0% |
| EPS (₹) | (0.10) | 0.04 | 0.33 | 1.19 | 0.80 | 715.45 | 0.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 24.90 | 13.60 | 13.60 | 13.60 | 0.01 | 0.01 |
| Reserves & surplus | - | 19.64 | 11.64 | 11.19 | 9.57 | 0.73 | 0.01 |
| Shareholders' funds (net worth) | - | 44.54 | 25.24 | 24.79 | 23.17 | 0.74 | 0.02 |
| Secured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | - | 0.00 | 4.24 | 9.58 | 8.16 | 0.00 | 0.01 |
| Total debt | - | 0.00 | 4.24 | 9.58 | 8.16 | 0.00 | 0.01 |
| Total liabilities | - | 44.54 | 29.48 | 34.36 | 31.32 | 0.74 | 0.03 |
| Assets | |||||||
| Gross block | - | 0.22 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 |
| Net block | - | 0.22 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
| Capital work in progress | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | - | 2.22 | 3.13 | 2.03 | 0.78 | 0.15 | 0.06 |
| Sundry debtors | - | 8.62 | 1.74 | 17.22 | 25.40 | 6.84 | 4.72 |
| Cash & bank balances | - | 0.21 | 0.12 | 0.15 | 3.09 | 0.03 | 0.00 |
| Loans & advances | - | 38.74 | 31.86 | 15.49 | 4.06 | 1.03 | 0.87 |
| Total current assets | - | 49.79 | 36.85 | 34.89 | 33.33 | 8.05 | 5.65 |
| Total current liabilities | - | 5.48 | 7.38 | 0.54 | 2.01 | 7.31 | 5.62 |
| Net working capital | - | 44.31 | 29.47 | 34.35 | 31.32 | 0.74 | 0.03 |
| Total assets | - | 44.54 | 29.48 | 34.36 | 31.32 | 0.74 | 0.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.12 | 0.15 | 3.09 | 0.03 | 0.00 | 0.02 |
| Net cash from operating activities | - | (14.62) | 5.32 | (4.35) | (26.43) | 0.03 | (0.02) |
| Net cash from investing activities | - | (0.26) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 |
| Net cash from financing activities | - | 14.97 | (5.34) | 1.42 | 29.49 | 0.00 | 0.00 |
| Net change in cash | - | 0.09 | (0.03) | (2.94) | 3.06 | 0.03 | (0.02) |
| Closing cash | - | 0.21 | 0.12 | 0.15 | 3.09 | 0.03 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +116.9% | +190.4% | -80.1% | +21.5% | +67.5% | +10.5% | - |
| EBITDA growth | +35.3% | -35.8% | +55.8% | -357.2% | +52.6% | - | - |
| PBT growth | - | -80.0% | -73.8% | +57.9% | +52.6% | +9997.0% | +9997.0% |
| Net income growth | -400.0% | -81.8% | -72.8% | +50.0% | +52.1% | - | - |
| Revenue CAGR (3Y) | +7.8% | -11.2% | -26.1% | +31.0% | +72.8% | - | - |
| EBITDA CAGR (3Y) | -27.0% | - | - | - | +425.4% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -0.9% | +0.7% | +10.9% | +8.0% | +6.4% | +7.1% | 0.0% |
| Return on capital employed | - | +0.4% | +1.9% | +7.0% | +9.1% | +249.4% | 0.0% |
| Return on net worth | - | +0.3% | +1.8% | +6.8% | +9.1% | +189.5% | 0.0% |
| Debt / equity | - | 0.06 | 0.28 | 0.37 | 0.34 | 0.01 | 0.25 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.25 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 94.08 | 202.50 | 4,078.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | 4.40 | 1.57 | 14.51 | 36.09 | 95.43 | 201.56 |
| Debtors turnover | - | 2.27 | 0.43 | 0.96 | 1.04 | 1.73 | 3.05 |
| EPS (₹) | (0.10) | 0.04 | 0.33 | 1.19 | 0.80 | 715.45 | 0.30 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 17.89 | 18.56 | 18.22 | 17.03 | 743.02 | 22.60 |
To see the full year-wise statements and ratios of Evoq Remedies Limited, buy the company report.
Board of directors of Evoq Remedies Limited
Evoq Remedies has 4 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bhumishth Narendrabhai Patel Also directs: Patron Exim Limited, Aquilae Worldwide Private Limited, Recurso Wellness Private Limited and 5 more | Managing Director | 01 Aug 2024 | 2 Years 3 Months | As last reported |
| Pushpa Joshi Also directs: Vintage Coffee and Beverages Limited, Avi Polymers Limited, Julien Agro Infratech Limited and 5 more | Director | 31 Mar 2025 | 1 Years 7 Months | As last reported |
| Harsh Mahendrakumar Kothari Also directs: Eforu Entertainment Limited | Director | 06 Sep 2024 | 2 Years 2 Months | As last reported |
| Narendrakumar Gangaramdas Patel Also directs: Patron Exim Limited, Aquilae Worldwide Private Limited, Recurso Wellness Private Limited and 5 more | Director | 11 Sep 2023 | 3 Years 2 Months | As last reported |
Deals & funding
Evoq Remedies Limited has 51 deals on record (41 market trades, 6 secondary share transfers, 3 funding rounds), with disclosed funding of ₹60.57 Cr; the latest was in June 2026.
Deals on record (5 of 51)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2025 | Market trade | ₹6.1 Lakh | Buyer: Yashiv Holdings Private Limited Seller: an individual |
| May 2025 | Market trade | ₹6.1 Lakh | Seller: Multiplier Share and Stock Advisors Private Limited |
| Feb 2025 | Market trade | ₹21.1 Lakh | Seller: Mansi Share and Stock Broking Private Limited , an individual |
| Feb 2025 | Market trade | ₹1.33 Cr | Buyer: Mansi Share and Stock Broking Private Limited , 2 individuals Seller: 2 individuals |
| Feb 2025 | Market trade | ₹62 Lakh | Buyer: Setu Securities Private Limited , Priyasha Meven Finance Limited , an individual Seller: Setu Securities Private Limited , Multiplier Share and Stock Advisors Private Limited , Priyasha Meven Finance Limited , an individual |
To see the full deal history of Evoq Remedies Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Evoq Remedies Limited has 1 court case on record: 1 filed by Evoq Remedies. All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, GUJARAT | Special civil application | Filed by the company against an individual | Disposed |
To see the full case history of Evoq Remedies Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Evoq Remedies Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Evoq Remedies has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAZCS6618L1ZI | Gujarat | Active | 27 Nov 2018 |
To see the full GST registrations and return filing status of Evoq Remedies Limited, buy the company report.
Recent activity
Evoq Remedies Limited has 14 board changes on record since 2023: 4 appointments and 10 cessations. The latest: Pushpa Joshi ceased to be Additional Director on 02 Jun 2025.
5 earlier events are in the company report.
Frequently asked questions
Evoq Remedies is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.
Evoq Remedies is a company under insolvency, formerly operating as a public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 February 2010 and is registered under CIN L46209GJ2010PLC059692. Listed on BSE: 543500. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Evoq Remedies reported revenue of ₹25.51 Cr for FY 2025-26 (up 116.9% YoY) based on standalone financials.
Evoq Remedies has 4 current directors:
- Bhumishth Narendrabhai Patel - Managing Director
- Pushpa Joshi - Director
- Harsh Mahendrakumar Kothari - Director
- Narendrakumar Gangaramdas Patel - Director
The latest financial statements of Evoq Remedies on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 17 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Evoq Remedies is L46209GJ2010PLC059692. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Evoq Remedies is a listed company as per MCA records. Its shares are listed on BSE (code: 543500).
Evoq Remedies has 1 court case on record: 1 filed by the company.
Evoq Remedies was incorporated on 24 February 2010. It is registered with the Registrar of Companies, Ahmedabad.
Evoq Remedies has 51 deals on record (41 market trades, 6 secondary share transfers, 3 funding rounds), with disclosed funding of ₹60.57 Cr; the latest was in June 2026.

